We are live on ! Find out more
RUBY

Rubius Therapeutics

Delisted

RUBY was delisted on the 6th of March, 2023.

76 hedge funds and large institutions have $771M invested in Rubius Therapeutics in 2019 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 29 increasing their positions, 22 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

32% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 22

22% more capital inflows, than outflows

Capital inflows: $50.4M | Capital outflows: $41.4M

1% more funds holding

Funds holding: 75 → 76 (+1)

9% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 11

0.63% more ownership

Funds ownership: 101.04% → 101.67% (+0.63%)

100% less call options, than puts

Call options by funds: $3K | Put options by funds: $950K

Holders
76
Holders Change
+1
Holders Change %
+1.33%
% of All Funds
1.49%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.08%
New
12
Increased
29
Reduced
22
Closed
11
Calls
$3​K
Puts
$950​K
Net Calls
-⁠$947​K
Net Calls Change
-⁠$920​K

RUBY Hedge Fund Activity: Q4 2019 in Review

76 of the 5,095 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics (RUBY) for Q4 2019, worth a combined $771M — up 22% from $632M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new RUBY positions and 11 closed out — a net gain of 1 holder — while 29 added to existing stakes and 22 trimmed.

The largest buyer was Capital World Investors, adding an estimated $20.5M. The largest seller was AllianceBernstein, cutting an estimated $26.8M.

  • 76 institutional investors held Rubius Therapeutics (RUBY) as of Q4 2019, up from 75 in Q3 2019.
  • Funds reported $771M of Rubius Therapeutics stock for Q4 2019, up 22% quarter-over-quarter.
  • 12 funds opened new Rubius Therapeutics positions in Q4 2019 and 11 closed out, a net change of +1 holder.
  • The largest Rubius Therapeutics buyer in Q4 2019 was Capital World Investors, an estimated $20.5M added.
  • The largest Rubius Therapeutics seller in Q4 2019 was AllianceBernstein, an estimated $26.8M sold.

Based on aggregated 13F filings for Q4 2019.